Semaglutide, 1.34 mg/mL

DRUG7 trials

Conditions

AlbuminuriaClozapineDiabetes Mellitus, Type 2GLP-1Metabolic DisturbanceOlanzapinePCOS (Polycystic Ovary Syndrome)Prediabetic State

Phase 1

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

CompletedNCT03598621

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2018-07-23End: 2019-01-17Updated: 2020-01-09

Phase 2

Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

CompletedNCT05193578

Jan FrystykPrediabetic State, Schizophrenia

Start: 2022-01-01End: 2024-05-01Updated: 2024-07-08

Phase 4

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

NCT04061200

Steno Diabetes Center CopenhagenType 2 Diabetes With Renal Manifestations

Start: 2019-11-01End: 2021-08-01Target: 80Updated: 2019-08-19

Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes

NCT04854083

Kirsi PietiläinenType2 Diabetes

Start: 2022-02-17End: 2025-08-31Target: 50Updated: 2022-03-31

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

Active, not recruitingNCT04892199

Anders Fink-Jensen, MD, DMSciClozapine, GLP-1, Metabolic Disturbance +3

Start: 2021-09-01End: 2026-08-01Target: 104Updated: 2024-09-25

Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

RecruitingNCT05702905

Peking University First HospitalPCOS (Polycystic Ovary Syndrome), Semaglutide

Start: 2023-05-09End: 2025-06-30Target: 75Updated: 2024-03-25

Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

Enrolling by invitationNCT06954090

Steno Diabetes Center CopenhagenAlbuminuria, Type 2 DM, Type 2 DM /Diabetic Nephropathy

Start: 2025-11-20End: 2027-05-31Target: 50Updated: 2025-12-22

Related Papers

Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks’ treatment with semaglutide

Cardiovascular Diabetology – Endocrinology Reports2026-01-19

Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.

2025-12-03

Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.

2025-11-011 citations

Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial

BMJ Open2024-03-015 citations

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

BMJ Open2023-01-0132 citations